Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical
course is characterized by progression disease from the early chronic phase (CP) to the fatal …

This chapter summarizes our knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …

Patients with splenomegaly and abnormally high leukocyte counts were first recognized in
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …

This book provides state-of-the-art reviews of key issues and recent developments relating
to chronic myeloid leukemia (CML), acquainting the reader with advances in research …

Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Leukemia was first recognized as a distinct nosological entity in the early part of the 19th
century and some of the early descriptions are highly suggestive of chronic myeloid …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

The first treatment of chronic myeloid leukemia (CML) included spleen x-radiation and
conventional drugs, mainly Busulfan and Hydroxyurea. This therapy improved the quality of …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …